Aptocrom Inc, formerly AP Healthcare Inc, is a Korea-based company primarily engaged in the pharmaceutical business. The Company operates its business through three segments. The Pharmaceutical Business segment is mainly engaged in the distribution and sale of drugs such as digestive organs medicine, outer skin medicine, nutrient tonic alteration and antibiotics. The Insulation Business segment is mainly engaged in the production, design, manufacturing and construction of industrial insulation. The Rental Business segment is mainly engaged in the real estate business such as offices and laboratories. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-06	₩1,721.00	+0.23%	5,582
26-07-06	₩1,717.00	+0.18%	5,703
26-07-03	₩1,714.00	-0.98%	7,410
26-07-02	₩1,731.00	0.00%	8,587
26-07-01	₩1,731.00	-0.86%	11,895

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 2026-07-07			5-day change	1st Jan Change
1,721.00 ^KRW	+0.23%		-1.71%	-65.58%

06-30	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-25	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI

Market Cap	19B 12.4M 10.86M 10M 9.28M 17.63M 1.18B 17.86M 120M 46.58M 580M 46.55M 45.53M 2.01B	P/E 2024	-2.12x	P/E 2025	-9.5x
Enterprise Value	1.8B 1.18M 1.03M 949K 881K 1.67M 112M 1.7M 11.36M 4.42M 55.11M 4.42M 4.32M 191M	EV / Sales 2024	4.85x	EV / Sales 2025	3.87x
Free-Float	41.27%	Yield 2024 *	-	Yield 2025	-

06-30	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-25	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-14	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-08	Aprogen Medicines Inc. announced that it has received KRW 12 billion in funding from APTOCROM Inc.	CI
05-07	APTOCROM Inc. announced that it has received KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
04-27	Aprogen Medicines Inc. announced that it expects to receive KRW 12 billion in funding from APTOCROM Inc.	CI
04-27	APTOCROM Inc. announced that it expects to receive KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
03-20	APTOCROM Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-15	APTOCROM Inc. announces Annual dividend	CI
11-13	APTOCROM Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-13	APTOCROM Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-24	AP Healthcare Inc. announced that it has received KRW 10 billion in funding from Aprogen, Inc.	CI
25-05-21	Aprogen Medicines Inc. agreed to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion.	CI

1 day	+0.23%
1 week	-1.71%
Current month	-1.43%
1 month	-13.65%
3 months	-48.47%
6 months	-67.03%
Current year	-65.58%

APTOCROM Inc. Stock

Stocks

A109960

KR7109960005

Pharmaceuticals

Valuation: APTOCROM Inc.

Chart: APTOCROM Inc.

Latest news : APTOCROM Inc.

Quotes and Performance

Course Extremes

Managers and Directors: APTOCROM Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,630	1,790
1 month	1,630	1,992
Current year	1,630	5,400
1 year	1,630	11,820
3 years	1,630	49,900
5 years	1,630	113,000
10 years	1,630	426,000

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	70	2022-03-22
Jong-Su Kang SAM	Sales & Marketing	62	-
Young-Suk Yeom AUD	Comptroller/Controller/Auditor	51	-

Director	Title	Age	Since
Jae-Seob Kim BRD	Director/Board Member	63	2017-01-09
Jung-Chool Kim BRD	Director/Board Member	70	2022-03-22
Soon-Kyu Park BRD	Director/Board Member	59	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOCROM INC.	+0.23%	-1.71%	-73.84%	-93.79%	12.37M
ELI LILLY AND COMPANY	+2.92%	+3.18%	+60.12%	+173.75%	1,070B
JOHNSON & JOHNSON	+3.50%	+5.59%	+72.71%	+68.39%	624B
ABBVIE INC.	+1.00%	+2.43%	+37.38%	+90.23%	450B
ROCHE HOLDING AG	+2.14%	-2.07%	+27.62%	+22.57%	328B
ASTRAZENECA PLC	+2.06%	+2.24%	+41.08%	+42.59%	292B
NOVARTIS AG	+1.44%	+0.28%	+30.05%	+49.50%	284B
NOVO NORDISK A/S	+1.98%	+4.08%	-25.78%	-39.02%	217B
AMGEN INC.	+0.51%	+2.15%	+26.27%	+69.17%	198B
GILEAD SCIENCES, INC.	+3.39%	+6.72%	+20.62%	+81.17%	161B
Average	+1.93%	+0.82%	+21.62%	+46.46%	362.44B
Weighted average by Cap.	+2.38%	+0.70%	+43.89%	+88.68%

	2024	2025
Net sales	16.4B 10.7M 9.37M 8.63M 8.01M 15.22M 1.02B 15.42M 103M 40.22M 501M 40.19M 39.31M 1.74B	9.81B 6.4M 5.6M 5.16M 4.79M 9.1M 610M 9.22M 61.8M 24.05M 300M 24.03M 23.51M 1.04B
Net income	-28.09B -18.33M -16.06M -14.79M -13.73M -26.07M -1.75B -26.42M -177M -68.89M -858M -68.85M -67.34M -2.98B	-5.56B -3.63M -3.18M -2.93M -2.72M -5.16M -346M -5.23M -35.03M -13.63M -170M -13.62M -13.33M -589M
Net Debt	-25.07B -16.36M -14.33M -13.2M -12.25M -23.26M -1.56B -23.57M -158M -61.47M -766M -61.43M -60.08M -2.66B	-17.19B -11.22M -9.83M -9.05M -8.4M -15.95M -1.07B -16.17M -108M -42.16M -525M -42.13M -41.21M -1.82B